What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the CheckMate 9ER trial indicates that cabozantinib plus nivolumab significantly improves overall survival (49.5 months vs. 35.5 months for sunitinib) and progression-free survival (16.6 months vs. 8.4 months for sunitinib). However, the evidence is uncertain regarding the effectiveness in different risk subgroups, which prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for cabozantinib plus nivolumab are within the range that NICE considers acceptable for intermediate- and poor-risk cancer, although they are above acceptable levels for favourable-risk cancer. This suggests marginal cost-effectiveness overall.
Is there quality-of-life evidence payers weigh? — Quality of life
Patient experts reported significant impacts on quality of life due to advanced renal cell carcinoma, indicating that treatment options like cabozantinib plus nivolumab could improve HRQoL. However, specific HRQoL data from validated instruments were not detailed in the document.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The treatment is reported to have a good safety profile, with manageable adverse effects compared to existing therapies. The document does not indicate any severe safety concerns that would undermine its value.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against appropriate standard-of-care options, including sunitinib and combination therapies like nivolumab plus ipilimumab. The committee concluded that these were the most relevant comparators for the target population.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population included a broad range of patients with advanced renal cell carcinoma, and the document discusses the relevance of different risk subgroups, although some limitations in subgroup analysis were noted.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment can be integrated into existing care pathways with minor adjustments, as it aligns with current treatment protocols for advanced renal cell carcinoma.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model suggests that the resource implications are manageable, with cost-effectiveness estimates deemed acceptable for certain patient groups, indicating a reasonable budget impact.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is primarily based on a well-conducted Phase III RCT (CheckMate 9ER) with a substantial sample size and follow-up duration, although some uncertainties in subgroup analyses were acknowledged.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the cost-effectiveness estimates, particularly for favourable-risk patients, the overall context supports the treatment’s use in the specified populations.
